DOCSLIB.ORG

Diabetic Foot Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diabetic Foot Infections Diabetic Foot Infections By Scott Bergman, Pharm.D., BCPS-AQ ID; and Punit J. Shah, Pharm.D., BCPS Reviewed by Douglas N. Fish, Pharm.D., FCCP, BCPS-AQ ID; Sonal Taylor, Pharm.D., BCACP; and Mary J. Thoennes, RPh, BCACP, NCPS LEARNING OBJECTIVES 1. Distinguish the factors that increase the risk of diabetic foot infections (DFIs) in a patient. 2. Assess the severity and extent of DFI on the basis of clinical tests and findings. 3. Evaluate a patient’s risk factors for multidrug-resistant organisms when selecting an appropriate empiric antimicrobial therapy for DFIs. 4. Analyze differences between therapeutic agents in pharmacokinetics and efficacy depending on the severity and extent of DFI. 5. Design an appropriate antimicrobial treatment and monitoring plan for a patient with a DFI with or without osteomyelitis. 6. Develop a plan to prevent diabetic foot ulcers in the patient with diabetes. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER According to the CDC, the number of Americans with a diagnosis of DFI Diabetic foot infection diabetes more than tripled between 1980 and 2012 (from 5.5 million DFO Diabetic foot osteomyelitis to 21.3 million) (CDC 2014). This number continues to rise, and with DFU Diabetic foot ulcer it, the number of patients at risk of microvascular and macrovascular HBOT Hyperbaric oxygen therapy complications. Foot problems are common in patients with diabe- MRSA Methicillin-resistant tes. Complications related to foot diseases in patients with diabetes Staphylococcus aureus include Charcot arthropathy, foot ulceration, infection, osteomyelitis, MSSA Methicillin-sensitive Staphylococcus aureus and limb amputation. However, the development of a diabetic foot ulcer (DFU) and subsequent infection is preventable. Pharmacists SSTI Skin and soft tissue infection play a vital role by monitoring, educating, and empowering patients. Table of other common abbreviations. This chapter focuses on the treatment of diabetic foot infections (DFIs), including osteomyelitis, in the primary care setting. Epidemiology and Impact Among patients with diabetes, diseases of the feet are more com- mon in men and in individuals older than 60 years. In their lifetime, about 25% of patients with diabetes will have a significant skin and soft tissue infection (SSTI) because of predisposing vascular insuf- ficiency, neuropathy, and impaired immunity. The most common foot infections are DFIs, and these patients have higher recurrence and hospitalization rates (Lipsky 2012). Diabetic foot infections decrease quality of life and increase morbidity, physical and emotional dis- tress, and health care costs. The number of hospital discharges for patients with diabetes and peripheral arterial disease, ulcer/inflam- mation/infection, and neuropathy doubled from 445,000 in 1988 to 890,000 in 2007 (CDC 2014). ACSAP 2016 Book 3 • Infection Primary Care 7 Diabetic Foot Infections Diabetic foot infections can spread contiguously to deeper muscle, difficulty walking and standing, loss of reflexes, and tissues, including bone. If the infection progresses, it may foot deformities, among other problems. Therefore, regular eventually be necessary to amputate the limb. The mean foot care is essential to prevent foot ulcers and associated hospital charge for one episode of foot or toe osteomyelitis morbidity and mortality in patients with diabetes. A compre- is around $19,000. In addition, in 1988–2009, hospital dis- hensive yearly foot examination is recommended; patients charges for nontraumatic lower-extremity amputation in with a history of ulcers, amputations, foot deformities, periph- patients with diabetes increased by 24% (CDC 2014). eral neuropathy, and peripheral arterial disease should have their feet examined at every visit. PATHOGENESIS Other risk factors for foot ulcers and infection include poor glucose control, which impairs immunologic function, espe- Risk Factors for DFUs and Infection cially action of polymorphonuclear (PMN) leukocytes, humoral Foot ulcers and infection usually occur after trauma. Several immunity, and cell-mediated immunity. In addition, patients factors predispose a patient with diabetes to foot ulcers and with diabetes may have decreased local and systemic inflam- infections. Patients with diabetes often have peripheral sen- matory responses to infection and poor wound healing because sory and motor neuropathy: diabetic neuropathy increases of peripheral arterial disease in the affected limb. Peripheral the risk of foot ulcers by 7-fold (Khanolkar 2008). Patients arterial disease is present in 20%–30% of patients with diabetes with diabetes lose the protective sensations for tempera- and in up to 40% of those with DFI; it is also the most important ture and pain and are often unaware of trauma to their feet. predictor for recovery after DFI (Schaper 2012). A multivariate Furthermore, motor neuropathy leads to wasting away of analysis showed that the risk factors most associated with developing foot infections were wounds that penetrated to the bone (OR 6.7), lasted more than 30 days (OR 4.7), were recurrent (OR 2.4), that had a traumatic etiology (OR 2.4), or that occurred BASELINE KNOWLEDGE STATEMENTS in patients with peripheral vascular disease (OR 1.9) (Lavery Readers of this chapter are presumed to be familiar 2006). Box 1-1 lists the risk factors for DFIs. with the following: • General knowledge of the pathophysiology that Complications leads to diabetic foot ulcers and infection in Breaks in skin expose underlying tissues to colonization by patients with diabetes pathogenic organisms including multidrug-resistant organ- • Spectrum of activity and pharmacokinetics of isms such as methicillin-resistant Staphylococcus aureus antimicrobials (MRSA). The resulting infection may begin superficially, but • Diabetes care standards with a delay in treatment and the impaired body defense mechanisms caused by neutrophil dysfunction and vascular Table of common laboratory reference values. insufficiency, it can spread to the contiguous subcutane- ous tissues and deeper structures (e.g., bone). Diabetic foot ADDITIONAL READINGS osteomyelitis (DFO) is present in up to 20% of mild-moder- ate DFIs and 50%–60% of severely infected wounds. Diabetic The following free resources have additional back- foot osteomyelitis increases the likelihood of surgical inter- ground information on this topic: vention, including amputation. • Infectious Diseases Society of America. Clinical Patients with DFIs may also present with signs of systemic practice guideline for the diagnosis and treatment inflammatory response syndrome, as manifested by at least of diabetic foot infections. Clin Infect Dis 2012;54:132-73. • Liu C, Bayer A, Cosgrove SE, et al. Practice guidelines by the Infectious Diseases Society of Box 1-1. Risk Factors for Diabetic Foot America for the treatment of methicillin-resistant Infections Staphylococcus aureus infections in adults and Presence of peripheral vascular disease in the affected children. Clin Infect Dis 2011;52:1-38. • limb • Stevens DL, Bisno AL, Chambers HF, et al. Practice • Poor glycemic control guidelines for the diagnosis and management of • Loss of protective sensation (i.e., neuropathy) skin and soft tissue infections: 2014 update by the • Traumatic foot wound Infectious Diseases Society of America. Clin Infect • Ulceration > 30 days Dis 2014;59:e10-59. • History of recurrent foot ulcers • American Diabetes Association (ADA). Standards • Previous lower-extremity amputation of Medical Care in Diabetes – 2016. Diabetes Care • Improper footwear 2016;39:S1-S112. • Wounds that penetrated to bone ACSAP 2016 Book 3 • Infection Primary Care 8 Diabetic Foot Infections two of the following: WBC greater than 12 × 103 cells/mm3 or Classification of Infection less than 4 × 103 cells/mm3 or 10% bands or more; respira- There are several published classification schemes and wound scoring systems; however, none is considered to be a tory rate greater than 20 breaths/minute or Paco2 less than 32 mm Hg; temperature greater than 38°C or less than 36°C; and gold standard. Examples of classification schemes are those heart rate greater than 90 beats/minute. from the International Working Group on the Diabetic Foot (IWGDF) and the Infectious Diseases Society of America (IDSA). The IWGDF classifies diabetic foot wounds using the ASSESSMENT acronym PEDIS (perfusion, extent, depth, infection, sensa- Is It Infected? tion). The PEDIS grades for DFI are 1–4, with the lowest grade Not all DFUs are infected. Therefore, DFIs must be diagnosed for no symptoms or signs of infection and the highest grade clinically, rather than only reviewing wound culture results, for presence of local and systemic signs and symptoms of because microorganisms can colonize all wounds. Local infection. The IDSA classifies the infection as uninfected, signs and symptoms of infection include swelling, warmth, mild, moderate, or severe. Grading or classification is tenderness, pain, erythema, and purulent secretions. Patients based on local and systemic manifestations, and extent of with peripheral neuropathy may be unable to describe pain infection. Table 1-1 summarizes the IWGDF and IDSA classi- at the infection site. In addition, patients with limb ischemia fication systems. secondary to peripheral vascular disease may not have ery- thema, warmth, or swelling around the infected ulcer. In these Microbiology patients, it may be appropriate to seek secondary signs of For uninfected wounds, specimen collection for culture is infection, such as abnormal coloration
Load more

Recommended publications
  • Defining Escherichia Coli As a Health-Promoting Microbe Against Intestinal Pseudomonas Aeruginosa
    bioRxiv preprint doi: https://doi.org/10.1101/612606; this version posted April 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Defining Escherichia coli as a health-promoting microbe against intestinal Pseudomonas aeruginosa Theodoulakis Christofi1, Stavria Panayidou1, Irini Dieronitou1, Christina Michael1 & Yiorgos Apidianakis1* 1Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus *Corresponding author, email: [email protected] Abstract Gut microbiota acts as a barrier against intestinal pathogens, but species-specific protection of the host from infection remains relatively unexplored. Taking a Koch’s postulates approach in reverse to define health-promoting microbes we find that Escherichia coli naturally colonizes the gut of healthy mice, but it is depleted from the gut of antibiotic-treated mice, which become susceptible to intestinal colonization by Pseudomonas aeruginosa and concomitant mortality. Reintroduction of fecal bacteria and E. coli establishes a high titer of E. coli in the host intestine and increases defence against P. aeruginosa colonization and mortality. Moreover, diet is relevant in this process because high sugars or dietary fat favours E. coli fermentation to lactic acid and P. aeruginosa growth inhibition. To the contrary, low sugars allow P. aeruginosa to produce the oxidative agent pyocyanin that inhibits E. coli growth. Our results provide an explanation as to why P. aeruginosa doesn’t commonly infect the human gut, despite being a formidable microbe in lung and wound infections.
    [Show full text]
  • P0469 In-Vitro Activity of Oritavancin Against Daptomycin And/Or Linezolid Resistant Enterococcus Faecium Clinical Isolates: a Single Centre Study
    P0469 In-vitro activity of oritavancin against daptomycin and/or linezolid resistant Enterococcus faecium clinical isolates: a single centre study Abhay Dhand*1, Nicholas Feola1, Leslie Lee1, Guiqing Wang1 1Westchester Medical Center Background: Oritavancin is a novel antibiotic with potent activity against a broad range of gram- positive organisms. Resistance to daptomycin, linezolid and other antibiotics among enterococcus is on the rise in many US hospitals. Oritavancin may provide an alternative antibiotic therapy for serious infections caused by such very resistant enterococci. The aim of this study was to evaluate in vitro antimicrobial susceptibility of oritavancin against enterococci with focus on Daptomycin non- susceptible (DNSE) and Linezolid resistant (LRE) clinical isolates. Materials/methods: DNSE and LRE clinical isolates were recovered from patients in a tertiary medical center in suburban New York City from May 2015 through December 2016. Daptomycin susceptibility was determined by MicroScan WalkAway™ System and confirmed by E-test. Susceptibility of oritavancin and linezolid was performed by broth microdilution using the Sensititre™ panel in accordance with the guidelines of the Clinical and Laboratory Standards Institute and package insert of the manufacturer. The isolates were confirmed by analysis of 16S rRNA gene sequence or by the MALDI Biobiotyper CA System™. Results: A total of 24 nonduplicate E. faecium clinical isolates were analyzed in this study. 19/24 isolates were DNSE (6-96 μg/ml), 4/24 were LRE (8-16 μg/ml) and 2/24 were both DNSE and LRE. The MIC50 and MIC90 of oritavancin against combined resistant enterococci isolates was 0.06 μg/ml and 0.25 μg/ml (range: 0.008 – 0.25 μg/ml) respectively.
    [Show full text]
  • Lung Infections Aeruginosa Pseudomonas Hypersusceptibility
    TLRs 2 and 4 Are Not Involved in Hypersusceptibility to Acute Pseudomonas aeruginosa Lung Infections This information is current as Reuben Ramphal, Viviane Balloy, Michel Huerre, Mustapha of September 29, 2021. Si-Tahar and Michel Chignard J Immunol 2005; 175:3927-3934; ; doi: 10.4049/jimmunol.175.6.3927 http://www.jimmunol.org/content/175/6/3927 Downloaded from References This article cites 51 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/175/6/3927.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLRs 2 and 4 Are Not Involved in Hypersusceptibility to Acute Pseudomonas aeruginosa Lung Infections1 Reuben Ramphal,* Viviane Balloy,† Michel Huerre,‡ Mustapha Si-Tahar,† and Michel Chignard2† TLRs are implicated in defense against microorganisms. Animal models have demonstrated that the susceptibility to a number of Gram-negative pathogens is linked to TLR4, and thus LPS of many Gram-negative bacteria have been implicated as virulence factors.
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Empiric Antimicrobial Therapy for Diabetic Foot Infection
    Empiric Antimicrobial Therapy for Diabetic Foot Infection (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2019) Infection Severity Preferred Empiric Regimens Alternative Regimens Comments Mild Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Outpatient management • Cellulitis less than 2 cm and • cephalexin 500 – 1000 mg PO q6h*,a OR • clindamycin 300 – 450 mg PO q6h (only if recommended ,a • cefadroxil 500 – 1000 mg PO q12h* severe delayed reaction to a beta-lactam) without involvement of deeper • Tailor regimen based on culture tissues and susceptibility results and True immediate allergy to a beta-lactam at MRSA Suspected: • Non-limb threatening patient response risk of cross reactivity with cephalexin or • doxycycline 200 mg PO for 1 dose then • No signs of sepsis cefadroxil: 100 mg PO q12h OR • cefuroxime 500 mg PO q8–12h*,b • sulfamethoxazole+trimethoprim 800+160 mg to 1600+320 mg PO q12h*,f Wound greater than 4 weeks duration:d Wound greater than 4 weeks duratione • amoxicillin+clavulanate 875/125 mg PO and MRSA suspected: q12h*,c OR • doxycycline 200 mg PO for 1 dose then • cefuroxime 500 mg PO q8–12h*,b AND 100 mg PO q12h AND metroNIDAZOLE metroNIDAZOLE 500 mg PO q12h 500 mg PO q12h OR • sulfamethoxazole+trimethoprim 800+160 mg to 1600/320 mg PO q12h*,f AND metroNIDAZOLE 500 mg PO q12h Moderate Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Initial management with • Cellulitis greater than 2 cm or • ceFAZolin 2 g IV q8h*,b OR • levoFLOXacin 750
    [Show full text]
  • Dalvance Generic Name: Dalbavancin Manufacturer1: DURATA Therapeutics Drug Class1,2,3,4: Antibiotic
    Brand Name: Dalvance Generic Name: dalbavancin Manufacturer1: DURATA therapeutics Drug Class1,2,3,4: Antibiotic Uses: Labeled Uses1: Treatment of adult patients with acute bacterial skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) Mechanism of Action:1,2,3,4 This drug is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall. Through this above mechanism it prevents cross-linking and interferes with cell wall synthesis. Dalbavancin is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes. Pharmacokinetics1,2,3,4 Tmax End of infusion time Vd 7-13L t1/2 346 hours Clearance .0513 l/h Protein binding (albumin) 93% (primarily to albumin) Bioavailability 100% Metabolism1,2,3,4: A minor metabolite- hydroxy-dalbavancin has been observed in the urine of healthy subjects, however quantifiable plasma concentrations have not been observed. Elimination1,2,3,4: Urine (33% as unchanged drug, 12% as hydroxy metabolite) Feces (20%) Efficacy: Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N Engl J Med 2014; 370:2169-2179. Study Design: Double blind, double dummy, randomized controlled study Description of Study: Discover 1 and Discover 2 were international, multicenter, randomized trials conducted from 2011 through 2012 at 54 and 86 investigative sites, respectively. The studies had the same design. Patients with acute bacterial skin and skin-structure infection were stratified then randomly assigned to receive dalbavancin intravenously on days 1 and 8 or vancomycin intravenously for at least 3 days with the option to switch to oral linezolid to complete 10 to 14 days of therapy.
    [Show full text]
  • Footprints an Informational Newsletter for Patients of APMA Member Podiatrists October 2017
    footprints an informational newsletter for patients of APMA member podiatrists october 2017 special EDITION include a DPM for diabetes prevention & Manage Ment According to the CDC, more than 100 million US adults are living with either diabetes or prediabetes. If you have diabetes or prediabetes, it is essential to include a podiatrist for proper diabetes prevention and management. In fact, podiatrists can reduce amputation rates up to 80 percent. In order for you not to become a part of that statistic, here are a few simple things you can do to keep your risk for diabetic ulcers and amputation low: Inspect feet daily. Check your Don’t go barefoot. Don’t go 1 feet and toes every day for 5 without shoes, even in your cuts, bruises, sores, or changes to own home. The risk of cuts and the toenails, such as thickening or infection is too great for those discoloration. with diabetes. Wear thick, soft socks. Avoid Never try to remove calluses, 2 socks with seams, which could 6 corns, or warts by yourself. rub and cause blisters or other Over-the-counter products can burn skin injuries. the skin and cause irreparable damage to the foot for people Exercise. Walking can keep with diabetes. 3 weight down and improve circulation. Be sure to wear See a podiatrist. Regular appropriate athletic shoes when 7 checkups by a podiatrist— exercising. at least annually—are the best WALKING CAN KEEP way to ensure that your feet WEIGHT DOWN AND Have new shoes properly remain healthy. 4 measured and fitted. Foot size IMPROVE CIRCULATION.
    [Show full text]
  • Diabetic Foot Ulcers
    REVIEW Review Diabetic foot ulcers William J Jeffcoate, Keith G Harding Ulceration of the foot in diabetes is common and disabling and frequently leads to amputation of the leg. Mortality is high and healed ulcers often recur. The pathogenesis of foot ulceration is complex, clinical presentation variable, and management requires early expert assessment. Interventions should be directed at infection, peripheral ischaemia, and abnormal pressure loading caused by peripheral neuropathy and limited joint mobility. Despite treatment, ulcers readily become chronic wounds. Diabetic foot ulcers have been neglected in health-care research and planning, and clinical practice is based more on opinion than scientific fact. Furthermore, the pathological processes are poorly understood and poorly taught and communication between the many specialties involved is disjointed and insensitive to the needs of patients. In this review, we describe the epidemiology, pathogenesis, operations above the ankle or those proximal to the and management of diabetic foot ulceration, and its effect tarsometatarsal joint, and a multinational WHO survey on on patients and society. The condition deserves more lower extremity amputation also included cases of attention, both from those who provide care and those who unoperated gangrene.13 fund research. Moreover, amputation is a marker not just of disease but also of disease management. The decision to operate Epidemiology is determined by many factors, which vary between Incidence and prevalence centres and patients. A high amputation rate might result Although accurate figures are difficult to obtain for the from high disease prevalence, late presentation, and prevalence or incidence of foot ulcers, the results of cross- inadequate resources, but could also reflect a particular sectional community surveys in the UK showed that 5·3% approach by local surgeons.
    [Show full text]
  • Clinical Review (Cubicin)
    Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) CLINICAL REVIEW Application Type NDA supplement Application Number(s) 21572 Priority or Standard Priority Submit Date(s) June 30, 2016 Received Date(s) June 30, 2016 PDUFA Goal Date March 30, 2017 (Major amendment) Division / Office DAIP/OAP Reviewer Name(s) Amol Purandare, MD Review Completion Date March 23, 2017 Established Name Daptomycin (Proposed) Trade Name Cubicin Therapeutic Class Cyclic Lipopeptide Applicant Cubist Pharmaceuticals Formulation(s) Injection Dosing Regimen 5 mg/kg (12-<18 years), 7 mg/kg (7-11 years), 9 mg/kg (2-6 years), and 10 mg/kg (1-< 2 years) Indication(s) Complicated Skin and Skin Structure Infections 1 Reference ID: 4075320 Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) Intended Population(s) Ages 1 year to <18 years Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT..........................................6 1.1 Recommendation on Regulatory Action ..............................................................6 1.2 Risk Benefit Assessment .....................................................................................6 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ....6 1.4 Recommendations for Postmarket Requirements and Commitments.................7 2 INTRODUCTION AND REGULATORY BACKGROUND .........................................7 2.1 Product Information .............................................................................................7
    [Show full text]
  • Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (Abssti)
    Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (abSSTI) 1. Patients meeting any of the following are NOT ELIGIBLE for dalbavancin therapy: a. History of hypersensitivity reaction to lipoglycopeptide antibiotics (vancomycin, televancin, dalbavancin, oritavancin). b. Patients with acute bacterial skin or skin structure infections such as superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure. c. Infection thought to be caused by gram-negative bacteria d. Infection due to an organism suspected or known to be resistant to dalbavancin or vancomycin 2. For outpatient use (i.e. ED) a. Contact infectious disease for authorization: ABX approval pager (see ON-CALL schedule) b. The following clinical criteria must be met: i. Pre-antibiotic blood cultures must be drawn. ii. Clinical condition expected to require ≥ 24 hours of IV antibiotics – must not qualify for oral antibiotic therapy. iii. Presence of cellulitis, major abscess or a wound infection associated with at least 75cm2 of erythema highly suspected or known to be caused by gram-positive bacteria. iv. The size of the infection must be clearly documented and/or outlined prior to leaving the ED, preferably with a photograph. v. Patient to be discharged to home ± home health (not to skilled nursing facility). c. Required follow up must be set up prior to leaving the ED: i. Must document patient contact info for follow up, preferably reliable cell phone number. ii. Must have follow up within 48-72H with Dr. Turnipseed (916-765-0196) or Rominski. 1. Email patient name, MRN, and phone number.
    [Show full text]
  • Dalbavancin (Dalvance®)
    DalbavancinDalbavancin (Dalvance (Dalvance®)®) IV Only Use requires formal ID Consult Activity: Coverage against Staphylococcus aureus (including MSSA and MRSA), Streptococcus pyogenes, Streptococcus agalactiae (Group B Strep.) and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) No clinical data, but activity in vitro vs. Enterococcus faecalis (vancomycin-susceptible strains only), Enterococcus faecium (vancomycin-susceptible strains only), vancomycin-intermediate S. aureus (not vancomycin-resistant strains) Criteria for Use: Treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive isolates Unable to use vancomycin (due to intolerance, MIC >2mg/L, or infection unresponsive to vancomycin despite therapeutic concentrations) Unable to use other agents (refer to empiric therapy for ABSSSI) Unacceptable Uses: Infections due to vancomycin-resistant enterococci Contraindicated in patients with known hypersensitivity to dalbavancin. Due to the possibility of cross-reactivity to glycopeptide, avoid in patients with previous glycopeptide hypersensitivity due to long half-life Dosing in Adults: Standard dose: Administration should be over 30 minutes 1 Dose Regimen: 1500mg IV once 2 Dose Regimen: 1000mg IV once, then 500mg IV on day 8 Renal dose adjustment: 1 Dose Regimen CrCl <30 mL/min 1125 mg IV 2 Dose Regimen CrCl <30 mL/min: 750mg IV once, then 325mg IV day 8 If receiving regularly scheduled hemodialysis: No dosage adjustment No hepatic dose adjustment anticipated Monitoring: Baseline BUN/Scr, AST/ALT/bili, CBC w/ diff, infusion-related reactions Considerations for Use: In clinical trials, 6 (0.9%) patients in the dalbavancin arm had ALT elevations greater than 5x ULN including 3 with ALT >10x ULN.
    [Show full text]
  • Biofire Blood Culture Identification System (BCID) Fact Sheet
    BioFire Blood Culture Identification System (BCID) Fact Sheet What is BioFire BioFire BCID is a multiplex polymerase chain reaction (PCR) test designed to BCID? identify 24 different microorganism targets and three antibiotic resistance genes from positive blood culture bottles. What is the purpose The purpose of BCID is to rapidly identify common microorganisms and of BCID? antibiotic resistance genes from positive blood cultures so that antimicrobial therapy can be quickly optimized by the physician and the antibiotic stewardship pharmacist. It is anticipated that this will result in improved patient outcomes, decreased length of stay, improved antibiotic stewardship, and decreased costs. When will BCID be BCID is performed on all initially positive blood cultures after the gram stain is routinely performed and reported. performed? When will BCID not For blood cultures on the same patient that subsequently become positive with be routinely a microorganism showing the same morphology as the initial positive blood performed? culture, BCID will not be performed. BCID will not be performed on positive blood cultures with gram positive bacilli unless Listeria is suspected. BCID will not be performed on blood culture bottles > 8 hours after becoming positive. BCID will not be performed between 10PM-7AM on weekdays and 2PM-7AM on weekends. BCID will not be performed for clinics that have specifically opted out of testing. How soon will BCID After the blood culture becomes positive and the gram stain is performed and results be available? reported, the bottle will be sent to the core Microbiology lab by routine courier. BCID testing will then be performed. It is anticipated that total turnaround time will generally be 2-3 hours after the gram stain is reported.
    [Show full text]